| abstract |
A method for treating an inflammatory disorder of the lower airways in a human subject in need thereof is described, including administering an effective amount of anakinra directly to the lower airways in the human subject; where the effective amount of anakinra is from about 0.1 mg to about 200 mg per day; and where the inflammatory disorder is selected from the group consisting of a toxic-inhalation lung injury, pulmonary langerhans cell histiocytosis, non-cystic fibrosis bronchiectasis, diffuse panbronchiolitis, acute respiratory distress syndrome (ARDS), reactive airways dysfunction syndrome (RADS), bronchiolitis obliterans organizing pneumonia (BOOP), and pneumonitis. |